Sionna Therapeutics is trading 10% down at $5.41 as broader risk-off conditions pressured U.S. equities on September 23, 2026. - Biotech stocks were rising, so sector weakness does not explain the decline. - Investors may still be reassessing disappointing SION-719 cystic-fibrosis results, the planned workforce reduction and the shift to a new Phase 2 regimen. - No new company announcement directly tied to the September 23 decline was identified; the move also appears to reflect lingering company-specific uncertainty.